DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure

Information source: Alberta Children's Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Intestinal Failure; Short Bowel Syndrome

Intervention: Glucagon-Like Peptide 2 (Drug); Glucagon like peptide-2 (Drug)

Phase: Phase 1/Phase 2

Status: Terminated

Sponsored by: Alberta Children's Hospital

Official(s) and/or principal investigator(s):
David Sigalet, MD PhD, Study Director, Affiliation: Alberta Children's Hospital


This protocol outlines a randomized,open label trial examining the safety, pharmacology and efficacy of Glucagon like peptide 2 (GLP-2) in infants and children with intestinal failure. The investigators hypothesize that GLP-2 given subcutaneously in these patients will be well tolerated, and have similar metabolism to what has been shown in adults. The investigators also expect to show an improvement in the tolerance of enteral nutrition, and a decreased requirement for intravenous feeding.

Clinical Details

Official title: Phase 1-2 Trial of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Frequency of Adverse events

Pharmacokinetics (Peak serum level. Area under the curve

Secondary outcome:

Changes in the Enteral Caloric intake

Nutritional Parameters

Mucosal Morphology

Intrinsic GLP-2 Production

Septic Episodes

Serum Citrulline Levels

Detailed description: GLP-2 (1-33) is a naturally occurring peptide which is important in controlling the function of the intestine. In previous studies our group has shown that serum levels of GLP-2 correlate with intestinal function in human neonates. Low levels of GLP-2 are predictive of intestinal malabsorption and the development of the so called "Short Bowel Syndrome". GLP-2 has been shown to be specifically trophic for the GI tract, especially for the small intestine. This proposal outlines a Phase 1 and 2 trial using subcutaneous administration, twice daily of GLP-2 in human infants and children with Intestinal Failure, typically from Short Bowel Syndrome, using varying doses, assigned in a prospective, randomized protocol, with open label monitoring. The investigational plan is to begin with the Phase 1 trial, administering GLP 2 at varying doses (infants assigned to doses of 5,10, or 20 μg/kg/day, children greater than 1 year dosed at 20 μg/kg/day, given via twice daily subcutaneous injection). Eligible subjects will be infants (less than 12 months corrected gestational age) with either major resection (remaining small intestine less than 40% of predicted length for gestational age), or demonstrated intestinal failure after intestinal resection/abdominal surgery/gastroschisis (Requirement for parenteral nutrition greater than 50% of total calories, more than 45 days after the last surgery). Infants will be allocated sequentially to a group (n = 6 per group) treated with GLP-2 at 5,10, or 20 μg/kg/day. Older children (greater than 1 year of age), requiring PN for >30% calories> one year post surgery will also be eligible; these patients will be dosed at 20 μg/kg/day (via twice daily subcutaneous injection) n= 7. Patients will be followed on the principle of intention to treat after initial randomization. The endpoints will be monitoring for safety, and recording of adverse events and a pharmacokinetic profile at 3 days. If the hormone is well tolerated these studies will be extended into a phase 2 study, for an additional 39 days; monitoring safety, patient tolerance of enteral nutrition, growth, citrulline levels, nutrient absorptive capacity, liver function and repeat pharmacokinetic studies.


Minimum age: N/A. Maximum age: 18 Years. Gender(s): Both.


Inclusion Criteria:

- Infants (< 1 year corrected gestational age) Infants with congenital anomalies, or

intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) will be eligible for treatment in the immediate post-operative period.

- Infants with intestinal resection or repaired gastroschisis who have demonstrated

dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine).

- Children (> 1 year corrected gestational age) Children with a requirement for >30% of

calories by PN more than 1 year (365) days post surgery will be eligible. Exclusion Criteria:

- Significant extra-intestinal disease (e. g., grade IV intraventricular hemorrhage,

severe hypoxic encephalopathy);

- Significant cardiovascular, hemodynamic or respiratory instability, as noted by 1)

the requirement for dopamine > 4 mcg/kg/min, 2) high frequency ventilatory support, 3) extracorporeal membrane oxygenation.

- Hepatic disease defined as direct bilirubin > 100 umol/L (5. 2 mg/dL)

- Renal disease defined as BUN > 80 or creatinine > 90 μmol/L (1. 5 mg/dL)

- Inborn errors of metabolism necessitating protein restriction or other special diet;

- Ongoing sepsis syndrome, as noted by refractory hypotension, thrombocytopenia,

acidosis, and/or bacteremia.

- Primary motility defect such as intestinal pseudo-obstruction.

- Absorptive defects (such as microvillus inclusion disease)

- Females who are post-pubertal must agree to comply with measures to prevent pregnancy

during the study phase.

- Coagulopathy which precludes the use of subcutaneous injections.

- Allergy to GLP-2 or any of the constituent of the GLP-2 IC-115 preparation.

Locations and Contacts

Alberta Children's Hospital, Calgary, Alberta T3B 6A8, Canada

Stollery Children's Hospital, Edmonton, Alberta T6G 2C8, Canada

British Columbia Children's Hospital, Vancouver, British Columbia V6H 3V4, Canada

Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada

Additional Information

Related publications:

Sigalet DL, de Heuvel E, Wallace L, Bulloch E, Turner J, Wales PW, Nation P, Wizzard PR, Hartmann B, Assad M, Holst JJ. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Pept. 2014 Jan 10;188:70-80. doi: 10.1016/j.regpep.2013.12.006. Epub 2013 Dec 22.

Starting date: January 2012
Last updated: December 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017